About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. ADR (NQ: IPHA )

2.356 -0.114 (-4.62%)
Streaming Delayed Price Updated: 1:52 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 989
Open 2.415
Bid (Size) 2.310 (6)
Ask (Size) 2.470 (5)
Prev. Close 2.470
Today's Range 2.356 - 2.470
52wk Range 1.810 - 3.540
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
From Innate Pharma SA
Via Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
From Innate Pharma SA
Via Business Wire

Performance

YTD
-13.38%
-13.38%
1 Month
-12.09%
-12.09%
3 Month
-13.06%
-13.06%
6 Month
+0.04%
+0.04%
1 Year
-20.14%
-20.14%

More News

Read More
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Its Participation in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Earnings Scheduled For March 21, 2024
Via Benzinga
Innate Pharma Announces Its Participation to Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
From Innate Pharma SA
Via Business Wire
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Its Participation to Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
From Innate Pharma S.A.
Via Business Wire
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
From Innate Pharma SA
Via Business Wire
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Leadership Change
From Innate Pharma SA
Via Business Wire
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
From Innate Pharma SA
Via Business Wire
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
From Innate Pharma SA
Via Business Wire
Innate Pharma to Host Virtual KOL Event on Lacutamab
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.